E2 Appoints Justin Farry as CFO to Enhance Financial Strategy and Growth

E2 Appoints New CFO

Endovascular Engineering, Inc. (E2), a leading medical device company, has made a notable addition to its leadership team with the appointment of Justin Farry as Chief Financial Officer (CFO). This strategic move comes as E2 advances its innovative endovascular therapies designed for the treatment of venous thrombo-embolism (VTE).

Justin Farry, with over 25 years of experience in the MedTech industry, brings a wealth of knowledge and expertise in financial management, operational strategies, and global business operations. His deep understanding of financial strategy, mergers and acquisitions, and enterprise performance will be crucial as the company prepares for the commercialization of its cutting-edge Hēlo™ Thrombectomy System.

Dan Rose, CEO of E2, expressed excitement about Farry's appointment. “Justin’s extensive experience in financial operations and his operational discipline will be invaluable as we transition into this next phase of growth,” he stated. “His skills are perfectly suited to help us navigate the intricate process of bringing our innovative technologies to market.”

Farry himself shares this enthusiasm, noting, “E2 is at an exciting inflection point. I’m looking forward to leveraging my experience in shaping strategies that not only enhance the company's financial standing but also impact patient lives dramatically.”

Before joining E2, Justin Farry served as Vice President of Financial Planning & Analysis at Axonics, Inc. During his time there, he played a significant role in overseeing budgeting processes, developing sales performance metrics, pricing strategies, and financial modeling. His contributions were pivotal in scaling Axonics to exceed $400 million in trailing twelve-month revenue. The company's successful trajectory culminated with its acquisition by Boston Scientific for an impressive $3.7 billion in 2024.

Farry has held CFO positions across various sectors and regions, successfully guiding private equity-backed and public companies through capital raises, process improvements, and lucrative exits. More recently, he has consulted with early-stage MedTech companies in both the U.S. and Europe as a Fractional CFO, focusing on fundraising and commercialization strategies.

The Hēlo™ Thrombectomy System, an innovative breakthrough in clot removal technology developed by E2, features a patented dual-action mechanism that integrates powerful aspiration with advanced clot remodeling capabilities. This technology aims to tackle VTE, a serious condition that can lead to life-threatening complications if not treated effectively.

As a venture-backed innovator, E2 is on a mission to change the standard of care in the treatment of VTE. Their approach combines clinical insight with engineering excellence, targeting the complex challenges involved in VTE intervention. The company is committed to developing and deploying groundbreaking solutions that can significantly enhance patient outcomes.

It is important to note that the Hēlo™ Thrombectomy System is currently an investigational device, restricted to investigational use as dictated by federal law. As E2 gears up for its next steps, Farry’s leadership is poised to make a profound impact on both the company and the landscape of MedTech as a whole.

For more details, visit the official website at E2 Hēlo and connect with them on LinkedIn @E2 - EndovascularEngineering.